Russell Investments Group
LOGC

Russell Investments Group’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Russell Investments Group’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-27,598
Closed -$250K – 3250
2020
Q3 		$250K Buy
+27,598
New +$209K ﹤0.01% 2686

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Russell Investments Group's LOGC Position: Q4 2020 in Review

Russell Investments Group sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2020, closing a stake of 27,598 shares — an estimated $250K sold.

Russell Investments Group first reported a position in LOGC in Q3 2020 and held it in 1 quarter. The position peaked at $250K in Q3 2020. 59 funds tracked by Wall St. Rank hold LOGC as of Q4 2020.

  • Russell Investments Group reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Russell Investments Group sold 27,598 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $250K.
  • Russell Investments Group first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Russell Investments Group's LogicBio Therapeutics, Inc. Common Stock position peaked at $250K in Q3 2020.
  • 59 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Russell Investments Group's 13F filing for Q4 2020, filed 8 Feb 2021.